share_log
Breakings ·  Jul 1 18:31
SpringWorks Therapeutics Inc - in H2 2024, Plans to File Marketing Authorization Application With EMA for Mirdametinib
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment